Form 4: Astera Labs Director Michael Hurlston Sells Shares Under 10b5-1 Plan

Director Michael Hurlston of Astera Labs sold a total of 67,548 shares of common stock on November 27, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Hurlston, a director at Astera Labs, sold 67,548 shares of common stock on November 27, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 28, 2024.
• The transactions occurred at various prices, ranging from $97.09 to $104.25 per share.
• The sales resulted in a decrease in Hurlston's direct holdings of Astera Labs common stock to 94,294 shares.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock sales by a director under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's performance.

Risks

• The sale of shares by a director could be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This is a routine disclosure of insider trading activity, which is common for publicly traded companies. The use of a 10b5-1 plan indicates that the sales were pre-planned and not based on any non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate insiders to avoid accusations of insider trading, similar to practices at companies like NVIDIA and AMD.
• The reported share sales are typical for directors and officers of publicly traded companies, and the disclosure is in line with SEC regulations, similar to filings from other tech companies such as Broadcom and Marvell.

Stakeholder Impact

• The sale of shares by a director could cause a minor negative reaction from shareholders, but the pre-planned nature of the sales should mitigate any significant impact.

Key Dates

Keywords

Astera Labs, Michael Hurlston, stock sale, Form 4, Rule 10b5-1, insider trading, share transaction, director